Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
BENYLIN is an oral solution combining diphenhydramine hydrochloride (first-generation antihistamine) and pseudoephedrine hydrochloride (nasal decongestant) for symptomatic relief of cold and allergy symptoms. This fixed-dose combination targets upper respiratory congestion, sneezing, and histamine-mediated symptoms through dual mechanism action. The product addresses the OTC/consumer health segment, targeting patients seeking multi-symptom cold and allergy relief.
Pre-launch stage indicates active commercialization buildout; teams are small but scaling rapidly for market entry with significant launch planning and field infrastructure development.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
BENYLIN represents a consumer health launch opportunity within Pfizer's OTC portfolio, requiring strong commercial execution in a mature category. Career advancement depends on launch success, market share capture, and operational efficiency rather than scientific innovation or rare disease expertise.
Worked on BENYLIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo